XML 44 R31.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2025
Segment Reporting [Abstract]  
Summary of Reportable Revenues by Geographic Regions The following table summarizes reportable revenue by geographic regions (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Testing services revenue
United States$72,073 $60,408 $195,181 $184,757 
Rest of World95 399 941 805 
$72,168 $60,807 $196,122 $185,562 
Product revenue
United States$7,593 $6,850 $21,293 $18,701 
Rest of World4,885 3,362 13,828 10,715 
$12,478 $10,212 $35,121 $29,416 
Patient and digital solutions revenue
United States$15,392 $11,824 $40,090 $32,102 
Rest of World17 40 86 126 
$15,409 $11,864 $40,176 $32,228 
Total revenue
Total United States$95,058 $79,082 $256,564 $235,560 
Total Rest of World4,997 3,801 14,855 11,646 

$100,055 $82,883 $271,419 $247,206 
Summary of Long-Lived Assets Consisting of Property and Equipment, Net by Geographic Regions
The following table summarizes long-lived assets, consisting of property and equipment, net, by geographic regions (in thousands):
September 30, 2025December 31, 2024
Long-lived assets:
United States$30,612 $33,286 
Rest of World233 266 
Total$30,845 $33,552 
Summary of Reconciliation of Revenue to Net Loss
The following table summarizes the reconciliation to net income (loss) (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2025202420252024
Revenue:
Testing services revenue
$72,168 $60,807 $196,122 $185,562 
Product revenue
12,478 10,212 35,121 29,416 
Patient and digital solutions revenue
15,409 11,864 40,176 32,228 
Total revenue
100,055 82,883 271,419 247,206 
Less:
Cost of testing services1
14,058 12,700 43,192 39,168 
Cost of product1
5,131 5,559 14,505 15,828 
Cost of patient and digital solutions1
10,050 7,417 25,323 20,537 
Personnel cost
33,915 29,186 93,988 86,557 
Professional and legal fees
10,307 10,224 32,847 32,430 
Research materials and clinical trials expense
1,791 3,526 9,022 11,730 
Depreciation and amortization expense
3,020 3,040 8,921 9,526 
Stock-based compensation expense
8,418 16,923 26,773 49,895 
Litigation settlement expense
— — 5,710 — 
Transformational initiative costs2
524 — 2,395 — 
Other segment items3
13,179 7,946 33,149 25,396 
Interest income, net
(2,013)(3,001)(7,160)(8,713)
Segment and condensed consolidated net income (loss)
$1,675 $(10,637)$(17,246)$(35,148)
1 Cost of testing services, cost of product and cost of patient and digital solutions include depreciation expense.
2 Transformational initiative costs consist of consulting expenses which relate to the Company's ongoing transformation strategy that the Company has undertaken as a series of initiatives focused on operational excellence, enterprise-wide efficiency, and long-term strategic growth, including rebranding costs.
3 Other segment items include the following: acquisition costs, software expenses, corporate expenses, rent and maintenance expense, travel and event related expense, one-time impairment charge on intangible asset and associated construction in progress, and other expenses (income).